Lexston Life Sciences Corp. (LEXT) AI Stock Analysis

• Market Cap: C$1.03M
• Dividend Yield: N/A
• Average Volume (3M): 4.56K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.20
• Revenue Growth: N/A
• EPS Growth: -36.54%
• Country: CA
• Employees: N/A
• Sector: Basic Materials
• Sector Strength: 66
• Industry: Biotechnology
• EPS (TTM): -0.05
• Shares Outstanding: 7,362,600
• 10 Day Avg. Volume: 5,177
• 30 Day Avg. Volume: 4,556
• PEG Ratio: 0.28
• Price to Book (P/B): 32.67
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -26.57
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 33 Underperform
• Price Target: ―

The company's stock is rated low due to significant financial challenges, including no revenue and consistent losses. Technical analysis suggests bearish momentum, and the valuation remains unattractive with a negative P/E ratio. While the recent private placement provides some liquidity, it may not be sufficient to address broader financial instability.

Lexston Life Sciences Corp. Business Overview & Revenue Model

Company Description

Lexston Life Sciences Corp. operates as a biotechnology company that provides cannabis testing and research services in Canada. The company also offers analytical testing for cannabis, pathogens, and toxins. In addition, it focuses on developing and validating methods for standardized manufacturing of plant derived psychedelics in the field of mental health and wellness. The company is based in Vancouver, Canada.

How the Company Makes Money

Lexston Life Sciences Corp. generates revenue through multiple streams, primarily focusing on the commercialization of its proprietary biotechnology products and services. The company earns money by licensing its technology to pharmaceutical companies and research institutions. Additionally, Lexston Life Sciences may engage in collaborative research and development partnerships, which provide both funding and shared intellectual property rights. The company also offers diagnostic testing services, which contribute to its earnings. Strategic partnerships and government grants may also play a role in supporting the company's financial growth.

Lexston Life Sciences Corp. Financial Statement Overview

Summary

Lexston Life Sciences Corp. is facing significant financial challenges typical of early-stage biotechnology firms. The lack of revenue and consistent losses signal high operational and financial risks. While the balance sheet shows low leverage, the declining equity and liquidity issues suggest the need for strategic changes or additional funding to achieve sustainability.

Income Statement

The company reported no revenue in the TTM period, indicative of its early stage or developmental phase typical in biotechnology. Net income has consistently been negative, reflecting ongoing losses. Gross profit margin, net profit margin, EBIT margin, and EBITDA margin calculations are not feasible due to zero revenue, indicating operational inefficiencies and financial instability.

Balance Sheet

The balance sheet shows a relatively high equity ratio, with a debt-to-equity ratio of 0.12, suggesting a conservative financing structure. However, the declining trend in total assets and stockholders' equity over recent periods raises concerns about financial sustainability. The return on equity is negative, aligning with the company's unprofitable status.

Cash Flow

Operating cash flow and free cash flow have been consistently negative, highlighting liquidity challenges. The free cash flow growth rate is negative, indicating deteriorating cash-generating ability. The company relies on financing activities to cover cash shortfalls, which may not be sustainable long-term.

Breakdown
TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
0.00	0.00	0.00	361.01K	149.11K	0.00
	Gross Profit
-6.62K	-26.39K	-29.80K	241.49K	60.10K	0.00
	EBIT
-592.73K	-674.72K	-871.53K	-1.86M	-106.04K	-6.48K
	EBITDA
-1.23M	-648.32K	-841.73K	-1.89M	-479.82K	-6.48K
	Net Income Common Stockholders
-1.43M	-867.71K	-1.11M	-2.32M	-876.13K	-6.48K
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
63.58K	390.40K	511.00K	590.49K	949.17K	170.76K
	Total Assets
655.04K	750.95K	814.30K	952.80K	1.10M	170.95K
	Total Debt
60.00K	0.00	0.00	0.00	0.00	0.00
	Net Debt
-3.58K	-390.40K	-511.00K	-590.49K	-949.17K	-170.76K
	Total Liabilities
142.42K	39.87K	11.21K	79.09K	38.81K	1.96K
	Stockholders Equity
512.62K	711.08K	803.10K	873.71K	1.06M	168.99K
Cash Flow		Free Cash Flow
-1.35M	-723.16K	-987.74K	-1.40M	-608.63K	-4.71K
	Operating Cash Flow
-1.34M	-523.18K	-987.74K	-1.40M	-483.16K	-4.71K
	Investing Cash Flow
-10.00K	-199.99K	0.00	-109.97K	812.32K	0.00
	Financing Cash Flow
1.30M	602.57K	908.24K	1.15M	620.01K	175.47K

Lexston Life Sciences Corp. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.14
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:LEXT, the sentiment is Negative. The current price of 0.14 is below the 20-day moving average (MA) of 0.16, below the 50-day MA of 0.17, and below the 200-day MA of 0.38, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 38.44 is Neutral, neither overbought nor oversold. The STOCH value of 76.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:LEXT.

Lexston Life Sciences Corp. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$1.99B	-1.26	-21.11%	5.30%	2.92%	-30.46%
LEXT	33 Underperform	C$1.03M	―	-258.31%	―	―	-36.54%
BRAXF		$1.03M	―		―	―	―
ENTBF		$959.16K	―	-106.50%	―	―	―
AWKNF		$2.86M	―		―	―	―
RIZE	54 Neutral	$2.27M	―	-44.38%	―	―	-20.10%
MOOD	42 Neutral	C$3.15M	―	-32.09%	―	-27.31%	81.88%

Lexston Life Sciences Corp. Corporate Events

Lexston Mining Corporation Secures $196,000 in Private Placement

Lexston Mining Corporation announced the successful closure of a non-brokered private placement, raising $196,000 through the issuance of 2,450,000 units. These funds will be used for general working capital, and the securities issued are subject to a four-month hold period. This move indicates Lexston’s ongoing efforts to bolster its financial position and support its mineral exploration projects in Canada.

Lexston Mining Corporation Launches Private Placement for Strategic Growth

Lexston Mining Corporation has announced a non-brokered private placement to raise up to $196,000 through the sale of 2,450,000 units priced at $0.08 each. The proceeds will be used for general working capital, with the issuance subject to Canadian Securities Exchange filing requirements and a four-month statutory hold period. This move could potentially strengthen Lexston’s financial position and support its ongoing mineral exploration projects, reinforcing its market presence.